Phathom Pharmaceuticals (PHAT) Common Equity (2022 - 2025)
Historic Common Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$422.5 million.
- Phathom Pharmaceuticals' Common Equity fell 12581.88% to -$422.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.5 million, marking a year-over-year decrease of 12581.88%. This contributed to the annual value of -$253.6 million for FY2024, which is 24852.05% down from last year.
- Per Phathom Pharmaceuticals' latest filing, its Common Equity stood at -$422.5 million for Q3 2025, which was down 12581.88% from -$405.8 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Common Equity high stood at $38.0 million for Q1 2022, and its period low was -$422.5 million during Q3 2025.
- Over the past 4 years, Phathom Pharmaceuticals' median Common Equity value was -$90.2 million (recorded in 2023), while the average stood at -$148.2 million.
- Per our database at Business Quant, Phathom Pharmaceuticals' Common Equity skyrocketed by 35142.86% in 2023 and then crashed by 142857.39% in 2024.
- Quarter analysis of 4 years shows Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then rose by 2.75% to -$72.8 million in 2023, then crashed by 248.52% to -$253.6 million in 2024, then plummeted by 66.63% to -$422.5 million in 2025.
- Its last three reported values are -$422.5 million in Q3 2025, -$405.8 million for Q2 2025, and -$338.4 million during Q1 2025.